Multiple organ failure, multiple organ dysfunction syndrome, and systemic inflammatory response syndrome: Why no magic bullets?

Archives of Surgery

Volumn 132, Issue 7, 1997, Pages 703-707

  Baue, Arthur E ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BRADYKININ ANTAGONIST; CENTOXIN; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J5; TAUROLIDINE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; ENDOTOXEMIA; GRAM NEGATIVE INFECTION; HUMAN; IMMUNOMODULATION; INFLAMMATORY DISEASE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SYNDROME DELINEATION; TREATMENT OUTCOME;

EID: 0030740131     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.1997.01430310017002     Document Type: Review

References (42)

1. Thomas L. Adaptive Aspects of Inflammation: Symposium of the International Inflammation Club. Kalamazoo, Mich: Upjohn Co; 1970.
2. Baue AE. Multiple, progressive, or sequential systems failure: a syndrome of the 1970s. Arch Surg. 1975;100:779-781.
3. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Meta CA, Balk RA. The methylprednisolone severe sepsis study group: sepsis syndrome: a valid clinical entity. Crit Care Med. 1989;17:389-393.
4. Bone RC. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med. 1991;114:332-333.
5. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-874.
6. Bone RC, Sibbald WJ, Sprung CL, et al. The ACCP-SCCM Consensus Conference on sepsis and organ failure. Chest. 1992;101:1481-1483.
7. Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638-1652.
8. Baue AE. What's in a name? an acronym or a response? Am J Surg. 1993;165: 299-301.
9. Blakiston's Gould Medical Dictionary. 3rd ed. New York, NY: McGraw-Hill Book Co; 1972.
10. Stehbens WE. Causality in medical science with particular reference to heart disease and atherosclerosis. Perspect Biol Med. 1992;36:97-119.
11. Stehbens WE. The concept of cause in disease. J Chronic Dis. 1985;38:947-950.
12. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ-system failure. Ann Surg. 1985;202:685-693.
13. LeGall J-R, Lemeshow S, Leleu G, et al, for the Intensive Care Unit Scoring Group. Customized probability model for early severe sepsis in adult intensive care patients. JAMA. 1995;273:644-650.
14. McCormick J. The multifactorial etiology of coronary heart disease: a dangerous delusion. Perspect Biol Med. 1988;32:103-108.
15. Ehrlich P, Morgenroth J. Ueber Hämolysins: Fünfte Mittheilung. Berl Klin Wochenschr. 1901;38:251-257.
16. Baue AE. The horror autotoxicus and multiple-organ failure. Arch Surg. 1992; 127:1451-1462.
17. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). JAMA. 1995;273:117-123.
18. Dellinger RP. Post hoc analyses in sepsis trials: a formula for disappointment? Crit Care Med. 1996;24:727-729.
19. Danner RL, Cobb JP, Suffredini AF, Eichacker PO, Natanson C. Nitric oxide in sepsis: role in inflammation and shock. Shock. 1995;3(suppl):61-62.
20. Natanson C, Eichacker PO, Suffredini AF, Danner DL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Shock. 1995;3(suppl):62.
21. Suffredini AF, Natanson C, Eichacker PO, Danner RL. Anticytokine therapies in septic shock. Shock. 1995;3(suppl):62.
22. Eichacker PO, Natanson C, Danner RL, Suffredini AF. The neutrophil as a therapeutic target in septic shock. Shock. 1995;3(suppl):62-63.
23. Tracey KJ, Fung Y, Hesse KR, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature. 1987;330:662-664.
24. Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol. 1990;145:3762-3766.
25. Mancilla J, García P, Dinarello CA. The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun. 1993;61:926-932.
26. Cannon JG, Friedberg JS, Gelfand JA, et al. Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans. Crit Care Med. 1992;20:1414-1419.
27. Luger A, Graf H, Schwarz H-P, Stummvoll H-K, Luger TA. Decreased serum interleukin 1 activity and monocyte interleukin 1 production in patients with fatal sepsis. Crit Care Med. 1986;14:458-461.
28. Sibbald WJ, Vincent J-L. Roundtable conference on clinical trials for the treatment of sepsis. Chest. 1995;107:522-527.
29. Sibbald WJ, Vincent J-L. Roundtable conference on clinical trials for the treatment of sepsis. Crit Care Med. 1995:23:394-399.
30. Bone RC. Sepsis and controlled clinical trials: the odyssey. Crit Care Med. 1995; 23:1165-1166.
31. Bone RC. Sepsis clinical trials: Don Quixote revisited. Chest. 1995;107:298-299.
32. Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA. 1992;268:3452-3455.
33. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24: 1125-1128.
34. Baue AE. Multiple organ failure, multiple organ dysfunction syndrome, and the systemic inflammatory response syndrome: where do we stand? Shock. 1994; 2:385-397.
35. Beal AL, Cerra FB, Multiple organ failure syndrome in the 1990s. JAMA. 1994; 271:226-233.
36. Eiseman B, Beart R, Norton L. Multiple organ failure. Surg Gynecol Obstet. 1977; 144:323-326.
37. Opal SM. Criticisms of clinical trials on sepsis and organ dysfunction. In: Gullo A, ed. Sepsis and Organ Failure. Trieste, Italy: APICE; 1996;4:29-41.
38. Neugebauer E, Schäfer S, Rixen D, Bouillon B, Modulation of the humoral mediator network in the treatment of shock and sepsis. In: Okada K, Ogata H, eds. Shock. Amsterdam, the Netherlands: Elsevier Science Publishers; 1996:275-288.
39. Reimund K-P, Greger B, Sitter H, et al. Development of clinical algorithms for standards in management for abdominal sepsis: a new chance for cytokine trials? Shock. 1996;5:47.
40. Buchman TG. Physiologic stability and physiologic state. J Trauma. 1996;41: 599-605.
41. Bone R. Why sepsis trials fail, a commentary. JAMA. 1996;276:565-566.
42. Goldie AS, Fearon KCH, ROSS JA, et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA. 1995;274:172-177.